title: Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
authors.affiliation: Case Western Reserve University, Cleveland, OH smg15@case.edu.
authors.forename: Saul
authors.initials: S
authors.lastname: Genuth
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005247:Feeding Behavior; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D008687:Metformin